CL2015000708A1 - Compuestos derivados de tert-butil-metil-amida del acido 5-(cloro-(piridin o fenil)-etinil)-piridina-2-carboxilico, como antagonistas de receptores metabotropicos de glutamato; su proceso de obtencion; composicion farmaceutica; y su uso para el tratamiento de ansiedad y dolor, depresion, enfermedad de parkinson, entre otras enfermedades. - Google Patents

Compuestos derivados de tert-butil-metil-amida del acido 5-(cloro-(piridin o fenil)-etinil)-piridina-2-carboxilico, como antagonistas de receptores metabotropicos de glutamato; su proceso de obtencion; composicion farmaceutica; y su uso para el tratamiento de ansiedad y dolor, depresion, enfermedad de parkinson, entre otras enfermedades.

Info

Publication number
CL2015000708A1
CL2015000708A1 CL2015000708A CL2015000708A CL2015000708A1 CL 2015000708 A1 CL2015000708 A1 CL 2015000708A1 CL 2015000708 A CL2015000708 A CL 2015000708A CL 2015000708 A CL2015000708 A CL 2015000708A CL 2015000708 A1 CL2015000708 A1 CL 2015000708A1
Authority
CL
Chile
Prior art keywords
anxiety
pyridin
parkinson
antagonists
pain
Prior art date
Application number
CL2015000708A
Other languages
English (en)
Inventor
Georg Jaeschke
Lothar Lindemann
Antonio Ricci
Daniel Rueher
Heinz Stadler
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2015000708A1 publication Critical patent/CL2015000708A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2015000708A 2012-10-18 2015-03-20 Compuestos derivados de tert-butil-metil-amida del acido 5-(cloro-(piridin o fenil)-etinil)-piridina-2-carboxilico, como antagonistas de receptores metabotropicos de glutamato; su proceso de obtencion; composicion farmaceutica; y su uso para el tratamiento de ansiedad y dolor, depresion, enfermedad de parkinson, entre otras enfermedades. CL2015000708A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12189015 2012-10-18

Publications (1)

Publication Number Publication Date
CL2015000708A1 true CL2015000708A1 (es) 2015-08-07

Family

ID=47049073

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000708A CL2015000708A1 (es) 2012-10-18 2015-03-20 Compuestos derivados de tert-butil-metil-amida del acido 5-(cloro-(piridin o fenil)-etinil)-piridina-2-carboxilico, como antagonistas de receptores metabotropicos de glutamato; su proceso de obtencion; composicion farmaceutica; y su uso para el tratamiento de ansiedad y dolor, depresion, enfermedad de parkinson, entre otras enfermedades.

Country Status (24)

Country Link
US (1) US9328070B2 (es)
EP (1) EP2909179B1 (es)
JP (1) JP5989253B2 (es)
KR (1) KR101656634B1 (es)
CN (1) CN104718191B (es)
AR (1) AR093043A1 (es)
AU (1) AU2013333984B2 (es)
BR (1) BR112015007991A2 (es)
CA (1) CA2882484A1 (es)
CL (1) CL2015000708A1 (es)
CR (1) CR20150143A (es)
EA (1) EA025668B1 (es)
ES (1) ES2599509T3 (es)
IL (1) IL237116A (es)
MA (1) MA38011B1 (es)
MX (1) MX2015004086A (es)
MY (1) MY170152A (es)
PE (1) PE20150628A1 (es)
PH (1) PH12015500496B1 (es)
SG (1) SG11201501375YA (es)
TW (1) TWI468393B (es)
UA (1) UA114934C2 (es)
WO (1) WO2014060394A1 (es)
ZA (1) ZA201500896B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA114008C2 (xx) * 2012-10-18 2017-04-10 Похідні етинілу як модулятори активності рецептора mglur5
TR201909160T4 (tr) 2015-07-15 2019-07-22 Hoffmann La Roche Metabotropik glutamat reseptörü modülatörleri olarak etinil türevleri.
WO2018015235A1 (en) 2016-07-18 2018-01-25 F. Hoffmann-La Roche Ag Ethynyl derivatives
KR102027368B1 (ko) * 2018-05-29 2019-10-01 서울대학교산학협력단 통증의 강도를 측정하는 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
KR20100033981A (ko) * 2007-06-03 2010-03-31 벤더르빌트 유니버시티 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법
US8853392B2 (en) * 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
MX2010003229A (es) * 2007-09-28 2010-04-07 Du Pont Composiciones de estabilizante liquido ionico.
TW201124391A (en) * 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
US8389536B2 (en) * 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8772300B2 (en) * 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives

Also Published As

Publication number Publication date
CN104718191A (zh) 2015-06-17
AR093043A1 (es) 2015-05-13
MX2015004086A (es) 2015-07-06
HK1208032A1 (zh) 2016-02-19
AU2013333984A1 (en) 2015-02-19
IL237116A (en) 2016-12-29
PE20150628A1 (es) 2015-05-11
EA201590722A1 (ru) 2015-07-30
CA2882484A1 (en) 2014-04-24
WO2014060394A1 (en) 2014-04-24
CR20150143A (es) 2015-04-30
US20150225344A1 (en) 2015-08-13
MY170152A (en) 2019-07-09
MA38011B1 (fr) 2016-10-31
JP2015534965A (ja) 2015-12-07
KR101656634B1 (ko) 2016-09-09
MA38011A1 (fr) 2016-01-29
PH12015500496A1 (en) 2015-04-27
EA025668B1 (ru) 2017-01-30
AU2013333984B2 (en) 2017-03-09
US9328070B2 (en) 2016-05-03
JP5989253B2 (ja) 2016-09-07
TW201420570A (zh) 2014-06-01
KR20150055045A (ko) 2015-05-20
EP2909179A1 (en) 2015-08-26
ES2599509T3 (es) 2017-02-02
BR112015007991A2 (pt) 2017-07-04
UA114934C2 (uk) 2017-08-28
PH12015500496B1 (en) 2015-04-27
TWI468393B (zh) 2015-01-11
SG11201501375YA (en) 2015-03-30
EP2909179B1 (en) 2016-10-05
ZA201500896B (en) 2016-08-31
CN104718191B (zh) 2016-06-29

Similar Documents

Publication Publication Date Title
HRP20160135T1 (hr) Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za lijeäśenje raka
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
MX2014000779A (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide.
MX341482B (es) Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
PH12015500746A1 (en) Benzamides
EA201400567A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
EA201500651A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
HK1220386A1 (zh) Ep4受体拮抗剂在软骨疾病的治疗中的用途
EA201792072A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
CL2013002424A1 (es) Compuestos derivados de (piridin-4-il)-bencilamidas como moduladores alostericos de nachr alfa-7; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades como alzheimer, ansiedad, esquizofrenia, parkinson, entre otras.
CL2016000387A1 (es) Derivados de amida como antagonistas de ácido receptor lisofosfatidico
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
PE20150629A1 (es) Derivados de etinilo como moduladores de la actividad del receptor de mglur5
MX2015007853A (es) Diazol amidas.
HK1218543A1 (zh) 新型磺酰胺trpa1受体拮抗剂
UA117154C2 (uk) Антагоністи s1p3
PH12015502692A1 (en) Ethynyl derivatives as metabotropic glutamate receptor antagonists
EA201500039A1 (ru) N-[4-(хинолин-4-илокси)циклогексил(метил)](гетеро)арилкарбоксамиды в качестве антагонистов андрогенного рецептора, их получение и применение в качестве лекарственных средств
UA114008C2 (xx) Похідні етинілу як модулятори активності рецептора mglur5
PH12015500496A1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
MX2015002514A (es) Antagonistas de los receptores de quimiocina.
BR112014006675A2 (pt) derivados de metanossulfonamida substituídos como ligantes de receptor vaniloide
BR112014011262A2 (pt) carboxamida com base em pirazolila substituída e derivados de ureia que portam uma porção de fenila substituída com um grupo contendo o como ligantes de receptor vaniloide
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.